DNDN – Radar Play
Traders Blog | Thursday 29 April 2010
The Food and Drug Administration Thursday approved a new type of prostate cancer treatment from Dendreon Corp. The therapy, Provenge, is approved for certain men with advanced prostate cancer who have failed treatment with hormone therapy.
“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” Karen Midthun, acting head of the FDA biologics center, said in a statement.
MarketClub has an interesting take on today’s DNDN action. Click Here for today’s FREE Trading Report + 100 score is given.
FREE DNDN Stock Analysis
One Response to “DNDN – Radar Play”
Comment on this post below.
Via RSS
Via Twitter
Breaking Stock Market News
Live Market Quotes
Sponsors
Archives
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
Links
[...] therapy, Provenge, is approved for certain men with advanced prostate cancer who have failed …More Here Report This [...]